{"Clinical Trial ID": "NCT00143390", "Intervention": ["INTERVENTION 1:", "- Exemestane", "One 25 mg exemestane tablet and placebo anastrozole were administered orally once daily after a meal. The study treatment was continued until disease progression or other stopping criteria were met.", "INTERVENTION 2:", "Anastrozole", "One 1 mg anastrozole tablet and placebo exemestane were administered orally once daily after a meal. The study treatment was continued until disease progression or other stopping criteria were met."], "Eligibility": ["Incorporation criteria:", "At the start of the study, the patient must have progressive or locally inoperable metastatic breast cancer.", "- Exclusion criteria:", "After receiving hormonal ovariectomy (e.g. Tamoxifene, LHRH-agonists) or chemotherapy for advanced/recurrent breast cancer"], "Results": ["Performance measures:", "Time of Progress (TTP) - Evaluation of the Expert Assessment Committee", "The tumour progression was determined by the expert assessment committee using RECIST version 1.0 as an increase of at least 20% in the sum of the longest diameters (LDS) of the target lesions compared to the smallest LDS since the start of the study. For participants with bone metastases only, at least 25% increase in the measurable lesion according to the General Rules for the Clinical and Pathological Study of Breast Cancer (The 14th Edition).", "Time limit: Until 2008 days of treatment", "Results 1:", "Title of the arm/group: Exemestane", "One 25 mg exemestane tablet and one placebo anastrozole were administered orally once daily after a meal. The study treatment was continued until disease progression or other stopping criteria were met.", "Total number of participants analysed: 147", "Median (95% confidence interval)", "Unit of measure: month 13.8 (10.8 to 16.5)", "Results 2:", "Title of the arm/group: Anastrozole", "One 1 mg anastrozole tablet and one placebo exemestane tablet were administered orally once daily after a meal. The study treatment was continued until disease progression or other stopping criteria were met.", "Total number of participants analysed: 145", "Median (95% confidence interval)", "Unit of measure: month 11.1 (10.8 to 16.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 19/149 (12.75%)", "Anemia 0/149 (0.00 %)", "Acute myocardial infarction 1/149 (0.67%)", "Pericardial infusion 1/149 (0.67%)", "- Prinzmetal angina 1/149 (0.67%)", "Meniere's disease 0/149 (0.00 %)", "Vertigo 0/149 (0.00 %)", "Cataract 2/149 (1.34 %)", "Ischemic colitis 1/149 (0.67%)", "Nausea 0/149 (0.00 %)", "Vomiting 0/149 (0.00 %)", "Chest pain 1/149 (0.67%)", "Adverse Events 2:", "Total: 19/149 (12.75%)", "Anemia 1/149 (0.67%)", "Acute myocardial infarction 0/149 (0.00 %)", "Pericardial infusion 0/149 (0.00 %)", "- Prinzmetal angina 0/149 (0.00 %)", "Meniere's disease 1/149 (0.67%)", "Vertigo 2/149 (1.34 %)", "Cataract 1/149 (0.67%)", "Ischaemic colitis 0/149 (0.00 %)", "Nausea 1/149 (0.67%)", "Vomiting 3/149 (2.01%)", "Thoracic pain 0/149 (0.00 %)"]}